enow.com Web Search

  1. Ads

    related to: insulin glargine trade names

Search results

  1. Results from the WOW.Com Content Network
  2. Insulin glargine - Wikipedia

    en.wikipedia.org/wiki/Insulin_glargine

    Insulin glargine sold under the brand name Lantus among others is a long-acting modified form of medical insulin, used in the management of type 1 and type 2 diabetes. [7] It is injected just under the skin . [ 7 ]

  3. List of largest selling pharmaceutical products - Wikipedia

    en.wikipedia.org/wiki/List_of_largest_selling...

    Trade name 2018 sales (million USD) 2017 sales (million USD) 1 adalimumab: ... Insulin glargine: Lantus Biologic Diabetes mellitus: Sanofi: 7,029 51 7 Bevacizumab:

  4. Insulin glargine/lixisenatide - Wikipedia

    en.wikipedia.org/wiki/Insulin_glargine/lixisenatide

    Insulin glargine/lixisenatide, sold under the brand name Soliqua among others, is a fixed-dose combination medication that combines insulin glargine and lixisenatide and is used to treat diabetes. The most common side effects include hypoglycemia (low blood glucose), diarrhea, vomiting and nausea (feeling sick).

  5. Does Medicare Cover Basaglar? - AOL

    www.aol.com/does-medicare-cover-basaglar...

    Some Medicare plans may cover Basaglar, but it varies by plan. Learn which plans cover Basaglar, how to find coverage, and what you can expect to pay.

  6. Insulin (medication) - Wikipedia

    en.wikipedia.org/wiki/Insulin_(medication)

    Insulin was first used as a medication in Canada by Charles Best and Frederick Banting in 1922. [85] [86] This is a chronology of key milestones in the history of the medical use of insulin. For more details on the discovery, extraction, purification, clinical use, and synthesis of insulin, see Insulin

  7. Lixisenatide - Wikipedia

    en.wikipedia.org/wiki/Lixisenatide

    In 2010, Zealand and Sanofi extended their license agreement to allow Sanofi to develop a combination therapy of lixisenatide with insulin glargine, which was Sanofi's best selling drug at the time, with sales of around €3 billion in 2009. [19] Sanofi planned to start the Phase III trial that year. [19]

  1. Ads

    related to: insulin glargine trade names